# This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients

> **NCT03100864** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 8 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Spesolimab

## Key facts

- **NCT ID:** NCT03100864
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-22
- **Primary completion:** 2019-08-05
- **Final completion:** 2019-10-24
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03100864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03100864, "This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03100864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*